A clinical trial found that participants who switched to monthly injections of a long acting GLP 1 drug were able to maintain much of their weight loss, offering a possible alternative to more frequent dosing.
• The treatment is designed to extend the effects of GLP 1 therapy, which can reduce appetite and support weight management.
• Participants who received monthly injections generally maintained their weight loss during the study period.
• The findings suggest that less frequent dosing could make long term treatment more convenient and potentially improve adherence.
• Researchers cautioned that the results do not establish whether monthly therapy is appropriate for everyone or how it compares with weekly medications over longer periods.
• As with other GLP 1 drugs, side effects and cost remain important considerations.
The results add to growing research into longer acting weight loss medicines as demand rises for treatments that can be sustained beyond the initial phase of losing weight. Further studies will be needed to assess the drug’s long term safety, effectiveness and real world use.